NPS Pharma reiterated by JMP at market outperform

NPS Pharmaceuticals Inc. was reiterated by JMP Securities analyst Charles Duncan at a buy rating with a price target on the stock of $22 per share following data presented by the company showing promise for its Preos in increasing bone strength, improving bone architecture and preventing vertebral fracture in postmenopausal women. NPS Pharma shares Wednesday were up $0.28, or 2.69%, at $10.70 on volume of 701,219 shares versus the three-month running average of 513,771 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.